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Abstract We explored the interactive effects of endothelial
nitric oxide synthase (eNOS) genotypes and cigarette smoking
on protein levels and enzyme activity in 33 postpartum placentas.
Whilst the eNOS protein levels were lower in the rare allele
(0.48 þ 0.11, n = 9 vs. 1.05 þ 0.10, n = 24, P6 0.01), the eNOS
enzyme activity was about 7-fold higher in the rare allele
(4556.2 þ 255.4 vs. 621.8 þ 180.5 cpm/mg/min, P6 0.01). Smo-
kers had lower eNOS protein levels (1.07 þ 0.09 vs. 0.50 þ 0.19,
P6 0.05) in both alleles. It reduced the eNOS activities only in
the rare allele (non-smokers: 6143.8 þ 251.2, n = 5, smokers:
2968.5 þ 259.4, n = 4, 52% reduction, P6 0.01). We conclude
that associations between eNOS polymorphism and protein levels
and enzyme activities are modifiable by smoking, the effects of
smoking are dependent on the eNOS genotypes.
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1. Introduction
Nitric oxide (NO) plays a key role in regulating physiolog-
ical functions in nearly all systems and has important impli-
cations for atherogenesis [1]. Both high and low NO can be
pathological while the physiological range of the NO levels is
determined by e¡ector and defense systems in the recipient
tissues. Biological NO is mostly produced enzymatically
from L-arginine by a family of three NO synthases (NOSs)
[2,3], neuronal NOS (nNOS or NOS1), inducible NOS (iNOS
or NOS2) and endothelial NOS (eNOS or NOS3). The eNOS
(7q35^36), con¢ned mainly to endothelium and modestly to
platelets, is essential in maintaining basal vascular NO pro-
duction which regulates blood £ow, particularly coronary ar-
tery blood £ow. Reduction in basal NO release may predis-
pose to hypertension, thrombosis, vasospasm and
atherosclerosis [4] ; and restoration of NO activity can induce
regression of pre-existing intimal lesions [5].
Among many reported polymorphic markers in eNOS gene,
associations between these polymorphisms and vascular dis-
eases have not been consistent [6^10]. We reported a signi¢-
cant interactive e¡ect between cigarette smoking and the
eNOS polymorphism on coronary artery disease (CAD) [11].
In smokers, but not in non-smokers, there was a signi¢cant
excess of homozygotes for the rare four repeats of 27 bp allele
(eNOS4/4) in patients with severely stenosed arteries, com-
pared with those with no or mild stenosis. However,
eNOS4/4 individuals also had signi¢cantly higher NO levels
than those with one or two common ¢ve repeat alleles
(eNOS5/5+eNOS5/4) in healthy non-smokers [12]. We also
reported a T3781CC base substitution at the promoter region
and the G894CT (Glu298CAsp) mutation at exon 7 of the
eNOS gene not associated with CAD nor NO levels [13,14].
Smokers have reduced endothelial dependent vessel relaxa-
tion, accelerated atherosclerotic plaque development and pre-
mature CAD [15,16]. Cigarette smoking is also a rich source
of exogenous NO which can a¡ect endogenous NO produc-
tion [17]. A recent study showed that cigarette smoke extract
can irreversibly inhibit pulmonary artery eNOS [18]. But the
exact molecular mechanisms of how cigarette smoke a¡ects
endogenous NO production and how endogenous NO attenu-
ates the cigarette e¡ects are not clear. Cigarettes could either
up- or down-regulate eNOS and/or iNOS or their necessary
cofactors. It could also directly block NO-initiated signal
transduction pathways for its biological e¡ects or directly re-
duce bioavailable NO by reacting with cigarette-generated O32
to produce more peroxynitrite.
In light of the inconsistent ¢ndings for the associations
between the reported eNOS polymorphisms and vascular dis-
eases, and the potential in£uence of cigarette smoking on the
associations, we hypothesized that eNOS expression is eNOS
genotype dependent and modi¢able by cigarette smoking. The
manifestations of certain eNOS genotype related phenotypic
traits are conditional on the presence or absence of a speci¢c
environmental factor, e.g. cigarette smoking. We wished to
explore the interrelations among eNOS polymorphisms,
eNOS gene expression, eNOS enzyme activity and cigarette
smoking. While it is practically di⁄cult to measure eNOS
expression in human coronary artery directly, placental tissue,
which is a rich source of eNOS and virtually devoid of nNOS
[19,20], can be used for such a purpose. We investigated our
hypothesis by measuring the genotypes and phenotypes of
eNOS in human placental tissues.
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2. Materials and methods
2.1. Placenta collection
Human placental tissues were collected from 33 pregnancies deliv-
ered by Caesarean sections in the third trimester. There were 21 full
term normal pregnancies and 12 pregnancies complicated with pre-
eclampsia and/or fetal intrauterine growth restriction. Within 30 min
after the delivery of the placenta, a section of placental tissue (V2
cmU2 cmU2 cm) was excised from mid-region of the placenta ex-
cluding the infarct tissues. The tissue was further divided into 10 small
aliquots before being snap frozen in liquid nitrogen. They were stored
at 380‡C until analysis (1^12 months). Placentas were collected from
the Department of Obstetrics and Gynaecology at Westmead Hospi-
tal. They were transported in dry ice to the Cardiovascular Genetics
Laboratory at Prince of Wales Hospital for determinations of eNOS
mRNA and protein levels and eNOS genotypes. The eNOS activity
was measured in the Orthopaedic Research Institute at St. George
Hospital. Samples were identi¢ed only by laboratory codes during
all experimental procedures. Participating researchers in each labora-
tory were cross-blinded for the results and identity of the samples
until the ¢nal statistical analysis. The study was approved by the
Ethics Committees of University of New South Wales and of Western
Sydney Area Health Service. Signed consent was obtained from every
mother before Caesarean section.
2.2. DNA extraction and eNOS genotyping
Tissues (100 mg) were minced and ground with a pre-chilled mortar
and pestle in 1.2 ml digestive bu¡er (100 mM NaCl, 10 mM Tris,
25 mM EDTA, 0.5% sodium dodecyl sulfate (SDS), 1 Wg/ml protein-
ase K, pH = 8.0). The mixtures were incubated in tightly capped tubes
at 50‡C for 16 h with shaking. This was followed by an addition of an
equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) and
centrifuging at 1700Ug for 10 min. DNA was precipitated with
1/2 volume 7.5 M ammonium acetate and two volumes of chilled
100% ethanol and centrifuged at 1700Ug for 2 min. DNA genotypes
for T3781CC base change at the promoter region, 27 bp repeat poly-
morphism at intron 4 and G894CT mutation at exon 7 were deter-
mined by PCR methods described previously [11,13,14].
2.3. RNA extraction and eNOS mRNA quantitation
Tissues (weight 100 mg) were cut into tiny pieces and homogenized
in 1 ml of Trizol Reagent (Life Technologies, Cat. No. 15596). RNA
was precipitated by isopropanol. The extracted RNA was then
DNase-treated before being dissolved in RNA storage solution
(1 mM sodium citrate, pH 6.4, Ambion, Bresatec Cat. No. AM-
7001). We used the Superscript1 Preampli¢cation System (Gibco
BRL, Cat. No. 18089-011) for the ¢rst strand cDNA synthesis primed
with oligo dT. The same amount of total RNA in duplicate was used
for ¢rst strand cDNA synthesis. This was followed by PCR using
eNOS speci¢c primers and 3 Wl target cDNA in a 20 Wl reaction
volume. The completed PCR reaction solution was mixed with exactly
7 Wl of loading dye, and exactly 10 Wl of which was loaded in duplicate
onto an 8% polyacrylamide gel electrophoresis (PAGE) gel in a Bio-
Rad Mini-Protein electrophoresis apparatus. Electrophoresis was con-
ducted for 30 min at 110 V. Gels were then stained with 250 ml
ethidium bromide solution (10 Wl 10 mg/ml ethidium bromide in
250 ml double-distilled H2O) for 10 min. The images were captured
with a Kodak Digital Science DC40 camera on a UV box with a 2 s
exposure time. Net intensity was read with a constant band area using
the Kodak Digital Science Electrophoresis Documentation and Anal-
ysis System. L-Actin was also ampli¢ed as a house-keeping gene and
was subjected to reverse transcription (RT)-PCR simultaneously with
the target eNOS cDNA ampli¢cation. The eNOS mRNA levels were
expressed as the ratio of the net eNOS band intensity to the net
L-actin band intensity. Given the intrinsic limitations that quantitative
RT-PCR has, our measurements can only be regarded as semi-quan-
titative. However, since we were comparing the di¡erences between
eNOS genotypes, the nature of semi-quantitation was satisfactory.
2.4. eNOS protein quantitation by Western blotting
An aliquot of tissue (weight 150 mg) was minced ¢nely with a sterile
razor blade. It was then transferred into a pre-chilled tissue grinder to
be homogenized on a setting of 12 strokes in 5 ml lysis bu¡er (5 mM
Tris^HCl, pH = 7.5, 1% Triton X-100 and protease inhibitor cocktail
tablet (Roche, Cat. No. 1873580)). The homogenized tissue was then
transferred into a pre-chilled Beckman centrifuge tube and centrifuged
at 20 000Ug for 30 min at 4‡C. The supernatant was recovered and
aliquoted into Eppendorf tubes. The total soluble protein concentra-
tion in the supernatant was determined by the Bradford method (Bio-
Rad, Cat. No. 500-0006). The extracted proteins were then diluted to
the same concentration for all samples in the following Western blot-
ting procedures. Protein samples were denatured by heating at 90‡C
for 3 min in denaturing bu¡er (0.5 M Tris pH 6.8, 28% glycerol, 6 mM
EGTA, 6% SDS, bromophenol blue 14% L-mercaptoethanol). Exactly
10 Wl of denatured sample was loaded in duplicate to the denaturing
SDS^PAGE gel. Proteins were separated by a 4.4% stacking gel and
10% separation gel (120 V for 90 min). The gel to nitrocellulose trans-
fer was conducted using a Bio-Rad transblot at 100 V for 3 h. The
transferred membrane was blocked overnight in blocking bu¡er (3%
BSA in TBS) with constant shaking. This was followed by incubating
with rabbit anti-human eNOS primary antibody (rabbit polyclonal
anti-synthetic peptide corresponding to the C-terminal sequence of
human eNOS, Cayman, Cat. No. 160880) diluted 1:1000 in 0.5%
polyvinyl-pyrrolidone (PVP) in TBS. Goat anti-rabbit IgG conjugated
with HRPO (Sigma, Cat. No. A-6154) was used as a secondary anti-
body diluted 1:40 000 in PVP/TBS. We used Supersignal Ultra chem-
iluminescent substrate to detect the signal (Pierce, Cat. No. 34075)
and the image was captured on an X-ray ¢lm with an exposure time
of 1 min (Kodak Scienti¢c Imaging Film, BIOMAX ML, Cat. No.
178 8207). The membrane was re-probed for the detection of the actin
band (42 kDa) using rabbit anti-human actin antibody (Sigma, Cat.
No. A5060) as a house-keeping control. The net intensity of the eNOS
band (V135 kDa) was analyzed by Kodak Digital Science Electro-
phoresis Documentation and Analysis System. The ratio of the net
intensity of the eNOS band to actin band of the same sample was
used as an estimation of the eNOS protein concentration.
2.5. NOS activity measurements
Samples were ground into a ¢ne powder in liquid nitrogen using a
mortar and pestle, and sonicated in ¢ve volumes of homogenization
bu¡er (50 mM Tris^HCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1%
L-mercaptoethanol, 2 Wg/ml leupeptin, 5 Wg/ml pepstatin A, 500 Wg/
ml 4-(2-aminoethyl)-benzenesulfonyl £uoride and 1 Wg/ml E-64). Con-
version of [3H]-L-arginine to [3H]-L-citrulline was measured in the
homogenates as previously described [21]. In brief, 30 Wl of tissue
homogenates was incubated in a reaction mixture containing 20 Wl
of [3H]-L-arginine (10 WCi/ml), 1 mM NADPH, 300 IU/ml calmodu-
lin, 5 WM tetrahydrobiopterin, with or without 2 mM CaCl2, with or
without 2.5 mM EGTA, with or without 2.5 mM NG-monomethyl-L-
arginine for 30 min at 37‡C. Reactions were stopped by adding 0.5 ml
of ice cold Tris bu¡er (pH 5.5) containing 1 mM EGTA and 1 mM
EDTA. Reaction mixtures were applied to Dowex 50W (Na form)
packed in chromatography spin columns for ion-exchange chromatog-
raphy and centrifuged at 1000Ug for 4 min. The radioactivity of the
eluent (recovered [3H]-L-citrulline) was measured by liquid scintilla-
tion. The data represented the mean of samples from each placenta,
each being assayed in quadruplicate. Since there are no nerve endings
in the placenta, the calcium dependent NOS activity in the placental
tissue is likely to represent eNOS. Two di¡erent adjustments were
used in presenting the NOS activities. The eNOS activities were ad-
justed by the amount of total proteins of the homogenates (cpm/mg/
min) to represent the total eNOS activity capacity of the tissue. The
activities were adjusted by the speci¢c eNOS protein levels to re£ect
the speci¢c eNOS enzyme activity per unit of eNOS protein.
2.6. Statistical analysis
Results are presented as mean þ S.E.M. and compared by ANOVA
for more than two groups and Student’s t test for between groups. A
factorial model of the univariate analysis of variance was employed to
assess the main e¡ects and interactive e¡ects of independent factors to
the phenotypic variances. The two-tailed P values are reported.
3. Results
3.1. E¡ects of cigarette smoking on eNOS expression and
enzyme activity
Among 33 samples, there were 21 full term normal preg-
nancies. The rest of the placentas (n = 12, 36%) were obtained
from pregnancies complicated with preeclampsia and/or intra-
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uterine growth retardation. Among complicated pregnancies,
four (33%) were smokers, but ¢ve of the 21 (23.8%) with
normal pregnancies were smokers. However, there was no
signi¢cant association between cigarette smoking and abnor-
malities during pregnancy. For all samples, eNOS protein
levels and enzyme activities were not correlated (r = 0.28,
n = 33, P = 0.116). There were also no statistically signi¢cant
correlations between the eNOS mRNA and eNOS protein
levels (r = 0.12, P = 0.34), and enzyme activities (r = 0.22,
P = 0.25). However, when the correlation analysis was con-
ducted among samples of non-smoking with normal pregnan-
cies, the correlation was signi¢cant between eNOS protein
levels and enzyme activities (r = 0.56, n = 16, P = 0.012).
Cigarette smoking appeared to down-regulate the eNOS
expression at the translational level since eNOS protein con-
centrations but not the mRNA concentrations were decreased
in smokers (Table 1). However, the eNOS activities also
tended to be higher in placentas with low eNOS protein con-
centration in smokers. This change was more dramatic when
the enzyme activity was adjusted by the eNOS protein con-
centration rather than the total protein concentration (Table
1). Cigarette smoking did not appear to have any e¡ect on the
iNOS activity (Table 2).
The eNOS gene expression in complicated pregnancies was
reduced at the transcriptional level. Both eNOS mRNA and
protein concentrations in placenta of complicated pregnancies
were low (Table 1). In contrast, the eNOS activity (adjusted
by the total protein amount used in the assay) was increased
among the placentas of complicated pregnancies. The increase
in eNOS enzyme activities was even more considerable after
they were adjusted by the amount of speci¢c eNOS protein.
Although calcium independent (iNOS) activity was also de-
tectable in the placental tissue, it was much lower than the
calcium dependent (eNOS) activity. There was no consistent
change in iNOS activity between placentas of normal and
complicated pregnancies (Table 2).
3.2. E¡ects of eNOS polymorphisms on eNOS expression and
enzyme activity
The 27 bp repeat polymorphism in intron 4 of the eNOS
gene was in linkage disequilibrium with the T3781CC substi-
tution in the promoter region (M2 = 10.969, P = 0.004). It
should be noted that two rare CC homozygotes for the
T3781CC substitution were also heterozygotes for the rare
four repeat allele at intron 4. However, neither the 27 bp
repeat polymorphism in intron 4 nor the T3781CC substitu-
tion in the promoter was in linkage with the G894CT muta-
tion at exon 7 (M2 = 0.869, P = 0.648, and M2 = 6.574, P = 0.160,
respectively).
The levels of eNOS mRNA and protein, and enzyme activ-
ities were assessed in relation to T3781CC substitution in the
promoter, the 27 bp repeat polymorphism at intron 4, and the
G894CT mutation at exon 7 (Table 3). The eNOS protein
concentrations in the CC genotype for the T3781CC substi-
tution were only 16% of the level in common TT homozy-
gotes. The eNOS mRNA concentrations also tended to be
lower in the CC homozygotes, but the di¡erence was not sta-
tistically signi¢cant. Both eNOS mRNA and protein levels in
TC heterozygotes were similar to those in TT homozygotes.
Whilst there was no signi¢cant di¡erence in the eNOS enzyme
activities adjusted by total protein concentration between dif-
ferent genotypes, the eNOS activities adjusted by the eNOS
protein levels were about 4-fold higher in the CC homozy-
gotes than that in TT homozygotes (Table 3).
Since the frequency of the 27 bp repeat polymorphism in
Caucasian population is very low [11], we were unable to
obtain placental samples homozygous for the rare four re-
peats allele. However, the eNOS mRNA and protein levels
Table 1
E¡ects of cigarette smoking and pregnancy complications on levels of eNOS mRNA and protein, and enzyme activities
Status (n) eNOS
mRNA Protein Activitya Activityb
Smoking No (24) 1.15 þ 0.11 1.07 þ 0.09 473.7 þ 72.2 997.5 þ 467.1
Yes (9) 1.14 þ 0.33 0.50 þ 0.19* 544.5 þ 145.3 1297.5 þ 460.7
Pregnancy Normal (21) 1.35 þ 0.15 0.95 þ 0.11 401.1 þ 53.2 697.0 þ 197.4
Complicated (12) 0.75 þ 0.09* 0.79 þ 0.16 676.9 þ 152.7* 1843.7 þ 993.8
Complicated pregnancies including preeclampsia and/or intrauterine growth retardation. The levels of eNOS protein and mRNA were presented
as the ratios of eNOS speci¢c band intensity to the house-keeping L-actin band intensity in quantitative Western blotting and RT-PCR. AN-
OVA was used to compare the di¡erences and two-tailed P values are reported.
aThe eNOS activity was adjusted by the levels of total protein of the tissue homogenates (cpm/mg protein/min).
bThe eNOS activity was adjusted by the levels of speci¢c eNOS protein determined in Western blotting.
*P6 0.05.
Table 2
E¡ects of cigarette smoking and pregnancy complications on total NOS, iNOS and eNOS activities
Status (n) NOS activities
Total NOS iNOS eNOS
Smoking No (24) 567.5 þ 88.8 93.8 þ 23.6 473.7 þ 72.2
Yes (9) 658.7 þ 176.3 114.3 þ 35.0 544.5 þ 145.3
Pregnancy Normal (21) 490.4 þ 60.7 89.3 þ 17.5 401.1 þ 53.2
Complicated (12) 796.5 þ 196.7 119.6 þ 47.6 524.6 þ 193.6
The total NOS activities include both calcium dependent and calcium independent NOS activities. They were measured by inclusion of calcium
in the reaction bu¡er. The iNOS activity was measured by the absence of calcium and the eNOS activity was deduced by subtracting the iNOS
from the total NOS activity. Since there is no nerve ending in placenta, the majority calcium dependent NOS is eNOS.
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in eNOS5/4 were already 45% of the levels in eNOS5/5 (Table
3). It is consistent with an allele dosage e¡ect and the e¡ect
was at the transcriptional level. The eNOS activities adjusted
by the eNOS protein levels, on the other hand, increased
nearly 5-fold in eNOS5/4 (Table 3).
For the G894CT mutation at exon 7, we observed a slight
but linear increase in the eNOS mRNA and protein levels
with the presence of one or two of the rare ‘T’ alleles suggest-
ing an allele dosage e¡ect (Table 3). However, the eNOS
enzyme activities decreased with the presence of the rare ‘T’
allele. This decrease was more prominent for the eNOS activ-
ities adjusted by eNOS protein levels. The eNOS activities in
TT homozygotes and GT heterozygotes were only about 20%
and 63% of the activities in GG homozygotes (Table 3). How-
ever, none of the di¡erences was statistically signi¢cant.
3.3. Interactive e¡ects of cigarette smoking and eNOS
polymorphisms on eNOS expression and enzyme activity
We assessed the e¡ect of cigarette smoking on eNOS pro-
tein concentrations in eNOS5/4 and eNOS5/5 genotypes sep-
arately. Cigarette smoking decreased the eNOS protein levels
from 1.09 þ 0.12 to 0.90 þ 0.27 (18% reduction) for eNOS5/5,
and from 0.42 þ 0.27 to 0.27 þ 0.28 (36% reduction) for
eNOS5/4. The di¡erence in eNOS levels between the
eNOS5/5 and eNOS5/4 genotypes was unaltered by cigarette
smoking. However, the eNOS activities were signi¢cantly de-
pressed by cigarette smoking only in the eNOS5/4 genotype
(non-smokers: 6143.8 þ 251.2, n = 5, smokers: 2968.5 þ 259.4,
n = 4, 52% reduction). Interestingly, enzyme activity was even
slightly elevated in the eNOS5/5 homozygotes (non-smokers:
521.3 þ 110.8, n = 19, smokers: 722.2 þ 251.1, n = 5, 38% in-
crease). Using a factorial model of the univariate analysis of
variance, we identi¢ed only the 27 bp repeat polymorphism at
intron 4 interacting with cigarette smoking and pregnancy
complications on eNOS enzyme activities whilst the main ef-
fects of the polymorphism remained signi¢cant (Table 4).
Although the levels of eNOS mRNA and proteins also
changed consistently indicating interactive e¡ects, they were
not statistically signi¢cant (Table 4). Neither the T3781CC
substitution nor the G894CT mutation interacted with ciga-
rette smoking or complicated pregnancies. Furthermore, in
the analytical model controlling for the e¡ects of these two
confounding factors, neither of these two base changes had
statistically signi¢cant main e¡ects on the eNOS activities.
4. Discussion
It is widely known that not every smoker develops athero-
Table 3
E¡ects of eNOS polymorphisms on levels of eNOS mRNA and protein, and enzyme activities
Genotypes (n) eNOS
mRNA Protein Activitya Activityb
T3781CC TT (17) 1.24 þ 0.12 0.95 þ 0.12 556.6 þ 110.4 709.8 þ 143.8
TC (14) 1.12 þ 0.22 0.94 þ 0.14 423.1 þ 66.4 1280.0 þ 798.6
CC (2) 0.49 þ 0.12 0.15 þ 0.01* 441.8 þ 286.5 2815.3 þ 1682.6
27 bp repeat at intron 4 5/5 (24) 1.32 þ 0.13 1.05 þ 0.10 446.5 þ 65.8 519.2 þ 73.2
5/4 (9) 0.69 þ 0.14* 0.48 þ 0.11** 617.0 þ 160.1 2572.8 þ 711.7**
G894CT GG (17) 1.02 þ 0.10 0.84 þ 0.11 577.7 þ 115.0 1349.1 þ 656.1
GT (13) 1.28 þ 0.24 0.98 þ 0.16 437.5 þ 55.0 846.9 þ 319.6
TT (2) 1.76 þ 0.54 1.16 þ 0.13 302.7 þ 63.8 269.6 þ 82.9
The levels of eNOS protein and mRNA were presented as the ratios of eNOS speci¢c band intensity to the house-keeping L-actin band inten-
sity in quantitative Western blotting and RT-PCR.
aThe eNOS activity was adjusted by the levels of total protein of the tissue homogenates (cpm/mg protein/min).




Interactions between cigarette smoking, pregnancy complications and eNOS intron 4 polymorphism on levels of eNOS mRNA and protein,
and activities (estimated mean þ S.E.M. by the model)
Smoking Pregnancy (n) Genotype (n) eNOS
mRNA Protein Activitya Activityb
No Normal (16) eNOS5/5 (13) 1.37 þ 0.16 1.05 þ 0.13 384.1 þ 102.6 477.8 þ 124.6
eNOS5/4 (3) 0.91 þ 0.29 0.73 þ 0.24 412.4 þ 185.0 684.1 þ 224.7
Abnormal (8) eNOS5/5 (6) 0.87 þ 0.24 1.13 þ 0.20 587.3 þ 151.1 564.7 þ 183.4
eNOS5/4 (2) 0.89 þ 0.58 0.10 þ 0.48 1 203.8 þ 369.9 11 603.5 þ 449.4
Yes Normal (5) eNOS5/5 (4) 1.89 þ 0.29 1.04 þ 0.24 363.4 þ 184.9 472.6 þ 224.7
eNOS5/4 (1) 0.61 þ 0.58 0.16 þ 0.48 728.3 þ 369.9 4 497.9 þ 449.4
Abnormal (4) eNOS5/5 (1) 1.04 þ 0.58 0.77 þ 0.48 746.5 þ 369.9 971.7 þ 449.4
eNOS5/4 (3) 0.36 þ 0.33 0.37 þ 0.28 657.2 þ 213.6 1 439.1 þ 259.4
After the other factors were controlled for in an univariate ANOVA of factorial model, the main e¡ects of the polymorphism, smoking and
complicated pregnancy on eNOS levels were F = 7.119, P = 0.013; F = 0.480, P = 0.495 and F = 0.392, P = 0.537. There was no signi¢cant interac-
tive e¡ect among three factors on eNOS levels. The main e¡ects of the polymorphism, smoking and complicated pregnancy on eNOS enzyme
activities adjusted by eNOS protein level were F = 300.865, P = 0.001; F = 42.987, P = 0.001 and F = 86.667, P = 0.001. The interactive e¡ects of
smoking vs. the polymorphism, complicated pregnancy vs. the polymorphism, and smoking vs. polymorphism vs. abnormal pregnancy on
eNOS activities were F = 55.387, P = 0.0001; F = 64.284, P = 0.0001 and F = 251.558, P = 0.0001, respectively.
aThe eNOS activity adjusted by the levels of total protein of the tissue homogenates.
bThe eNOS activity adjusted by the levels of speci¢c eNOS protein.
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sclerosis and not every genetically susceptible individual, e.g.
familial hypercholesterolaemia, develops myocardial infarc-
tion. It is the coexistence of adverse environmental factors
on the background of genetic susceptibility which determines
the initiation and progression of atherosclerosis. Our previous
study has illustrated a gene^environment interaction model at
population levels by demonstrating that the four repeat allele
in intron 4 of the eNOS gene is associated with an increased
CAD risk [11]. However, we have also reported that the rare
four repeat allele is associated with higher basal NO produc-
tion in healthy non-smokers [12]. Since a reduced basal NO
production is often associated with an increased CAD risk,
the results of the two studies appear to be paradoxical. The
results of the present study have provided some explanations
for the apparent paradoxical ¢ndings in our patient and
health populations that the rare allele was associated with
CAD risk in patient smokers but higher NO levels in control
non-smokers [11,12].
We found that the eNOS mRNA and protein levels were
signi¢cantly lower in the eNOS5/4 than the eNOS5/5 geno-
types. In contrast, the eNOS enzyme activity was about 5-fold
higher in the eNOS5/4 than that in the eNOS5/5, which is
consistent with the rare allele being associated with a higher
NO production [12]. However, whilst cigarette smoking de-
creased the eNOS protein levels in the common and the rare
allele, it reduced the eNOS enzyme activities only in the
eNOS5/4 genotype to less than half of the non-smokers. The
enzyme activities for the eNOS5/5 were even modestly ele-
vated in cigarette smokers. Therefore, although the rare four
repeat allele may produce more NO in non-smokers, the NO
generating capacity by the eNOS is seriously compromised in
smokers in the rare four repeat allele but not the common ¢ve
repeat allele. The ¢ndings provide mechanisms at the tissue
level for the genotype dependent and environment speci¢c
model in regulating eNOS expression and enzyme activity.
Although no homozygote for the rare four repeat allele was
available for the present study, the e¡ect of the heterozygote
was so large that an allele dosage e¡ect can be expected.
Whilst the polymorphism-related regulation in eNOS gene
expression is most likely to be at the transcriptional level,
mechanisms for the association between the low eNOS protein
levels and high enzyme activities remain to be explained. It is
di⁄cult to speculate that the changes in eNOS level could
directly cause protein conformational changes which result
in a more active form of eNOS. It is known that the eNOS
normally functions as dimers conditional on the presence of
many cofactors [22^25]. The level changes in eNOS protein
could indirectly in£uence the bioavailability of cofactors or
the e¡ective formation of eNOS dimers, and therefore the
eNOS enzyme activity. Furthermore, it is intriguing that cig-
arette smoking regulates eNOS enzyme activity also genotype
dependent on the intron 4 polymorphism. The cigarette smok-
ing only down-regulated the eNOS enzyme activities in the
rare four repeat allele carriers. Clearly more studies are
needed to understand the mechanisms.
We further reported that the T3781CC substitution at the
promoter region was also associated with reduced eNOS pro-
tein levels. As we observed for the intron 4 polymorphism, the
eNOS enzyme activities tended to be elevated in the rare allele
homozygotes. It adds yet another example that a low eNOS
level was coincidental with an elevated eNOS enzyme activity.
Since these two polymorphisms are in linkage disequilibrium
and both CC homozygotes are also four repeat heterozygotes,
it is not clear which of these two sequence variants is func-
tional in gene regulation. Lacking of an allele dosage e¡ect
and no interaction between cigarette smoking and the
T3781CC substitution would indicate that the T3781CC sub-
stitution is not functional. On the other hand, the G894CT
(Glu298CAsp) mutation at exon 7 had a slightly elevated
eNOS protein level. But the eNOS speci¢c enzyme activity
was lower in the mutant, which also appears to be allele
dose dependent. There is no interactive e¡ect between the
mutation and cigarette smoking on either eNOS levels or
eNOS enzyme activities. Whilst no study has revealed that
this amino acid change can cause any conformational change
in eNOS protein, our results suggest that it could reduce en-
zyme activity.
In conclusion, we have demonstrated a genotype dependent
and environmental speci¢c model in regulating eNOS expres-
sion and enzyme activity at the tissue level. This model has
wider application to other phenotypic variables. It indicates
that recognition of a speci¢c genotype^environment pair, e.g.
eNOS intron 4 polymorphism^cigarette smoking, would have
signi¢cant impacts on understanding the aetiology of athero-
genesis and implementing e¡ective measures in prevention and
intervention. Further studies at the DNA level are needed to
understand the molecular mechanisms responsible for the ge-
notype dependent and environment speci¢c changes observed
in populations and tissues.
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